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ABSTRACT We have recently described a nonnuceoside
compound that specifcally inhibits the reverse transcriptase of
human immunodeficiency virus type 1 (HIV-1), the causative
agent of AIDS. This compound, nevirapine (BI-RG-587), in-
teracts with highly conserved tyrosine residues at positions 181
and 188 in the reverse t iptase to inhibit the recombinant
enzyme and virus replication in cell culture with 50% inhibi-
tory concentrations in the 40 nM range. HIV-1 variants
resistant to nevirapine emerged with passage in cell culture in
the presence of drug. This resistant phenotype was stable with
continued passage in the absence of drug. These mutants had
a substitution of cysteine for the tyrosine at position 181.
Introduction of this mutation into the recombinant enzyme
increased the inhibitory concentration of nevirapine 100-fold.
Substitution of cysteine for tyrosine at residue 181 into the
wild-type viral genome conferred a similar reduction in sus-
ceptibility to nevirapine. Mutants were also resistant to a
tetrahydroimidazo[4,5,1-jk][1,4]benzodlazepin-2(1H)-one and
-thione derivative and two 6-phenylthiouracil derivatives but
retained their sensitivity to the other reverse transcriptase
inhibitors, 3'-azido-3'-deoxythymidine and foscarnet.
Infection by human immunodeficiency virus type 1 (HIV-1)
requires reverse transcriptase (RT)-catalyzed synthesis of
double-stranded DNA (1, 2). Inhibition of this enzymatic
reaction by the nucleoside analogue drug zidovudine (3'-
azido-3'-deoxythymidine; AZT) has provided the first clini-
cal benefit for HIV-infected patients (3-5). Prolonged ther-
apy with AZT has resulted in the emergence of drug-resistant
variants with changes in the RT gene (6, 7). A class of
nonnucleoside compounds including nevirapine (BI-RG-587)
and the tetrahydroimidazo[4,5,1-jkl[1,4]benzodiazepin-
2(1H)-one and -thione (TIBO) series inhibit RT by a different
mechanism (8-11) and, therefore, are effective against the
AZT-resistant mutant viruses (12). Nevirapine is a potent,
highly specific inhibitor that binds to HIV-1 RT by a mech-
anism that is noncompetitive with respect to primer, tem-
plate, nucleotide, and tRNA (9, 10). The residues to which
nevirapine binds, Tyr-181 and -188 (13, 14), flank an amino
acid sequence that has been shown by mutational analysis to
be critical for enzyme activity and that is conserved among
all RNA-dependent polymerases but whose functional role is
not understood (15). Although the two tyrosine residues have
been absolutely conserved among HIV-1 isolates, there are
different amino acids at that site in other related lentiviral
RTs (16). Therefore, we anticipated that some mutations
might be tolerated in the nevirapine binding sites ofthe HIV-1
enzyme that would permit replication but render the virus
resistant to the drug. Such mutations would be expected to
emerge under the selective pressure of prolonged therapy
with nevirapine in AIDS patients. In these studies, we
describe several independent isolates of nevirapine escape
mutants selected in cell culture in both a laboratory strain and
a low passage patient isolate ofHIV-1. It seems likely that the
single nucleotide transition in the codon for amino acid 181
from TAT for tyrosine to TGT for cysteine that we observed
in these variants may arise in patients undergoing nevirapine
treatment.
MATERIALS AND METHODS
Virus Passage and Selection for Resistance in Cell Culture.
HIV-lBRu and the AZT-sensitive San Diego isolate A018A (6)
were passaged in 0, 1, or 10 juM nevirapine in wells of48-well
plates (Costar) containing 105 CEM cells in 1.0 ml of RPMI
1640 medium containing 100 units of penicillin per ml, 100 pug
of streptomycin per ml, 2 mM glutamine, 1 pug of Polybrene
per ml, and 10% fetal bovine serum. The multiplicity of the
initial infection was 1 tissue culture ID50 per cell. Passages
were performed weekly by adding 150 A.l of the infected
culture supernatant to a final culture vol of 1 ml containing 105
uninfected CEM cells. The remaining supernatant was frozen
in aliquots at -700C.
Drug Susceptibility Assays by Plaque Reduction. HeLa cells
expressing CD4 (HT4-6C cells) (17) were used in a plaque
(syncytial focus) reduction assay as described (6, 18). Briefly,
24-well culture plates containing HT4-6C cell monolayers
were inoculated with virus in various concentrations of
antiviral drug in medium. Duplicate wells were prepared for
each dilution, and the percentage plaque reduction was based
on the control value without drugs. The IC" was calculated
with the median effect plot (19). Nevirapine and R82913, a
TIBO derivative (8), were synthesized in-house. Foscarnet
was purchased from Fairfield Chemicals (Blythwood, SC).
1-Ethoxymethyl-5-ethyl-6-(phenylthio)uracil and 1-benzyl-
oxymethyl-5-ethyl-6-phenylthio-2-thiouracil were the gener-
ous gift of M. Baba (Fukushima, Japan) (20).
Nucleic Acid Sequencing. Viral isolates found to be resistant
to nevirapine and their parental strains were sequenced by
asymmetric PCR (21). Both strands were sequenced to con-
firm results. The primers obtained from Genosys (The Wood-
lands, TX) used for sequencing are indicated with their
nucleotide numbers (22): sense (2583-2597), 5'-CCAAAG-
TAGCATGAC-3'; antisense (2795-2768), 5'-ACCCATC-
CAAAGGAATGGAGGTTCTl-C-3'.
Abbreviations: HIV, human immunodeficiency virus; RT, reverse
transcriptase; AZT, 3'-azido-3'-deoxythymidine; TIBO, tetrahy-
droimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione.
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Preparation of Recombinant RT Enzymes. The HIV-1 RT
expression clone, which is also available from the National
Institutes of Health AIDS Research and Reference Reagent
Program was obtained from Yale University (23). Mutant
construct HIV-1 RT Cys-181 was made by oligonucleotide-
directed mutagenesis (24) using protocols available commer-
cially (Bio-Rad, Richmond, CA). The mutant RT construct
was first cloned into the Nco I/HindIII sites of phagemid
vector pGEM3Zf(+) (Promega), which was modified to con-
tain an Nco I site in the polylinker region, and the clones were
selected by nucleotide sequence analysis. The construct was
then subcloned into pKK233-2 (Pharmacia), the same expres-
sion vector as wild-type RTs. The mutation was again con-
firmed by nucleotide sequencing. Highly purified wild-type
and mutant RTs were prepared as described (10).
Western Blot Analysis. Highly purified mutant and wild-
type RT enzymes were run on an SDS/polyacrylamide gel
and blot-transferred onto a nitrocellulose filter. The blot
reacted with monoclonal antibody directed against HIV-1 RT
and was developed with reagents and protocols from
Promega.
Binding of BI-RJ-70, Photoaffinity Analog of Nevirapine.
Wild-type and mutant RTs were labeled with [3H]BI-RJ-70,
a photoaffinity analog probe that binds to the same site on
HIV-1 RT as nevirapine under conditions in which the
photoaffinity probe labeled only the p66, but not the p5l,
subunit of the wild-type HIV-1 RT heterodimer (10). Samples
were then fractionated by SDS/PAGE, and the gel was
fluorographed with Entensify (NEN) and exposed to x-ray
film at -70'C for 3 days.
Polymerase Assays. AZT 5'-triphosphate was obtained
from Raymond F. Schinazi through the AIDS Research and
Reference Reagent Program, Division of AIDS, National
Institute of Allergy and Infectious Diseases, National Insti-
tutes of Health. The other drugs were obtained as indicated.
Highly purified enzymes were used for measurements of 50%o
inhibitory concentrations (IC50) with compounds. IC50 values
for nevirapine, R82913, and foscarnet were derived from
RNA-directed DNA polymerase assays, using poly(rC)-oligo-
(dG) as template primer in the following conditions: 50 mM
Tris HCI, pH 7.8/60 mM NaCl/2 mM MgCl2/24 nM
poly(rC) oligo(dG)j0 (Pharmacia)/600 nM [3H]dGTP (NEN)
(specific activity, 11 Ci/mmol; 1 Ci = 37 GBq)/20 mM
dithiothreitol/0.02% 3-[(3-cholamidopropyl)dimethylammo-
nio]-1-propanesulfonate in a total vol of 60 ,ul. IC50 values for
AZT 5'-triphosphate were measured on poly(rA)-oligo(dT) as
template primer with the following reaction components: 50
mM Tris-HCl, pH 7.8/60 mM NaCl/2 mM MgCl2/5 nM
poly(rA)300 oligo(dT)12_18 (Pharmacia)/700 nM [3H]TTP
(NEN; specific activity, 20 Ci/mmol). The reaction mixture
was incubated for 60 min at 25°C. Acid-insoluble products
were collected on glass fiber filters, and radioactivity was
determined by LKB Beta Plate scintillation counting.
Construction and Analysis of Mutant Viral Genomes. A
recombinant provirus containing the tyrosine to cysteine
mutation at amino acid 181 of the polymerase was con-
structed by transfer of an EcoRV/PflMI restriction enzyme
fragment spanning the mutation in the recombinant RT
enzyme into a plasmid containing the remainder of a repli-
cation-competent provirus, R7/3/BH10; this provirus was
used for the wild-type control. One microgram of wild-type
or mutant proviral DNA was introduced into 106 Jurkat cells
by the DEAE-dextran method (25). After distributing the
transfected cells into wells with different concentrations of
nevirapine, the course of viral replication was monitored by
the appearance of cytopathic effect and quantitation of RT
activity and p24 antigen in the supernatant.
Detection ofWild-Type and Mutant Sequence at Amino Acid
181. Wild-type or mutant sequence present in the superna-
tants ofpassaged virus was detected by amplification with the
isothermal, self-sustained sequence replication method (26)
and differential hybridization using a bead-based sandwich
hybridization technique that has been applied to AZT resis-
tance mutations (27). Trisacryl Oligobeads 90-46, and 32p_
labeled detection oligonucleotides 91-115, 91-87, and 91-86
were used to detect the following amplification products:
90-46, GT AGC ATG ACA AAA ATC TTA GAG CC;
91-115, CTTA GAA ATA GGG CAG CA; 91-87, ATA GTT
ATC TAT CAA TAC AT; 91-86, ATA GTT ATC TGT CAA
TAC AT. Oligonucleotide 91-115 detects all RT amplification
products independent of genotype. Oligonucleotides 91-87
and 91-86 span the codon for amino acid 181 and are specific
for the wild-type sequence (Tyr-181) or the mutant sequence
(Cys-181), respectively. Complementary and noncomple-
mentary targets were differentiated by a series of increasingly
more stringent washes with continuous monitoring for la-
beled detection oligonucleotide. The total radioactivity ofthe
pooled washes and the detection oligonucleotide remaining
bound to the Oligobeads were determined by Cerenkov
counting, and the femtomoles of product captured were
calculated based on the percentage of the total cpm that
remained hybridized to the beads (27).
RESULTS
Selection of Nevirapine-Resistant Virus. Two strains of
HIV-1 were each passaged in the presence of either 1 or 10
,uM nevirapine. Passaged supernatants were tested for infec-
tivity and drug-susceptibility phenotype. With the laboratory
strain HIV-lBRU, plaques were detected in supernatants from
the first passage in the presence of 1 ,uM nevirapine and
between passages 6 and 12 at 10 ,uM. The virus population in
supernatants after 20 passages in 1 ,LM nevirapine was
'100-fold less susceptible than the parental virus, although
passage 12 supernatants contained virus with an apparently
intermediate susceptibility (Fig. 1). Strain A018A, a 1986
virus isolate, generated sufficiently high titers of virus to
detect plaques at passage 3 with 1 ,uM nevirapine and at
passage 7 with 10 ,uM nevirapine. The drug susceptibilities of
these isolates were 100-fold reduced compared to the control
virus passaged in the absence of drug.
Cross-Resistance of the Resistant Phenotype. The nevi-
rapine-resistant virus displayed no cross-resistance to fos-
carnet or AZT; however, the susceptibility to other nonnu-
cleoside inhibitors, a TIBO derivative, and two 6-phenyl-
thiouracil derivatives, was significantly reduced (Table 1).
Cross-resistance to neither dideoxycytosine nor dideoxyin-









FIG. 1. Susceptibility of HIV-1BRU passaged in the presence of 1jLM nevirapine. m, Passage 0; *, passage 12; A, passage 20.
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Table 1. Susceptibility of nevirapine-resistant variant to other RT inhibitors
IC", ,M
Nevirapine AZT-TP Foscarnet TIBO E-EPU E-BPU-S
Virus
Passage 0 0.04 0.01 30 0.05 0.02 0.003
Passage 12 10.0 0.01 30 0.2 1.0 1.0
Recombinant enzyme
Wild type 0.06 ± 0.01 0.04 ± 0.02 18.6 ± 11.1 0.13 ± 0.03 ND ND
Y181C mutant* 4.83 ± 0.71 0.02 ± 0.01 17.2 ± 9.3 1.62 ± 0.08 ND ND
The 1 MM nevirapine passage 12 supernatant of strain A018A and the parental virus were used.
Polymerase assays were performed in triplicate at each drug concentration, and averages of triplicate
data were used for analysis. Results from two independent experiments were analyzed to derive IC50
± SE. ND, not done; E-EPU, 1-ethoxymethyl-5-ethyl-6-(phenylthio)uracil; E-BPU-S, 1-benzyloxy-
methyl-5-ethyl-6-phenylthio-2-thiouracil.
*Tyr-181 to Cys-181 mutation.
Stability of the Resistant Phenotype. The passage-12-
resistant variant ofA018A passaged in 10juM nevirapine was
then passaged 19 additional times in drug-free medium. The
resistant phenotype remained unchanged in the absence of
selective pressure, and its growth rate was not distinguish-
able from the parental virus (data not shown).
DNA Sequence Analysis of the Nevirapine Binding Site. To
determine the mechanism by which these mutants had be-
come resistant to the nonnucleoside inhibitors, we sequenced
the region of the viral genome that encodes the nevirapine
binding site in RT. The sequence of 171 bases ofDNA from
two independent isolates of A018A and one of HIV-lBRU
revealed a single nucleotide change from the wild-type se-
quence in the codon for the tyrosine residue at codon 181
(TAT to TGT), resulting in a mutation to cysteine.
Emergence of the Cys-181 Mutation by in Vitro Selection.
The supernatants from each passage of virus in the presence
of nevirapine were monitored for the presence of the wild-
type and mutant sequence at codon 181, part of the nevi-
rapine binding site (13, 14), utilizing a recently devised
methodology of self-sustained sequence replication amplifi-
cation and differential bead-based sandwich hybridization. In
experiments utilizing two strains of HIV-1 and two drug
concentrations, mutant sequence was detectable in a mixture
as early as the first passage and a pure population of mutant
sequence developed in the second passage in one experiment
(Table 2). The virus examined in Fig. 1 proved to be a mixture
ofwild-type and mutant virus at passage 12 and mutant alone
at passage 20.
Effect of the Re Mutation of Recombinant RT. To
determine whether or not the single change of Tyr-181 to
Cys-181 was sufficient to confer nevirapine resistance to the
RT enzyme, the substitution was made in the recombinant
clone of the gene encoding HIV-1 RT. Purified recombinant
wild-type or mutant RT proteins were tested for enzyme
activity and for sensitivity to nevirapine. The recombinant
enzyme containing Cys-181 was as active as the wild-type
enzyme containing Tyr-181 (data not shown). However, the
IC50 of the Cys-181 mutant for nevirapine and TIBO was 100-
and 10-fold higher, respectively, than that of the wild-type
enzyme (Table 1). To determine the mechanism by which the
Cys-181 mutation conferred resistance to nevirapine, we
tested the ability of the mutant enzyme to bind to [3H]BI-
Table 2. Passages first displaying indicated genotype
HIV-1BRU A018A
Genotype 10 AM 1 MLM 10 MM 1 AM
Wild type 1 1 1
Mixture 3 17* 1
Cys-181 only 5 5 2
*Only 20 passages were tested.
RJ-70, the radiolabeled photoaffinity analog of nevirapine
(13). BI-RG-70 has IC50 values for wild-type and mutant
enzymes of 0.06 and 0.51, respectively. The-labeling of the
mutant was dramatically reduced compared with the labeling
ofwild-type RT, even though Western blot analysis indicated
that comparable amounts of wild-type and mutant enzyme
were analyzed (Fig. 2). These data indicated that a single A
to G mutation in the RT gene of HIV-1 was sufficient to
inhibit binding of the photoaffinity analog and to render the
enzyme resistant to nevirapine.
Effect of Cys-181 Substutio in the HIV-1 Genome. It was
possible that the single base change in the RT gene was
sufficient to render the enzyme insensitive to nevirapine but
that some compensatory mutation elsewhere in the viral
genome was required for efficient viral replication. This
possibility was tested by introducing that mutation into the
cloned wild-type viral genome. After transfection of the
mutant provirus into Jurkat cells, the virus grew with kinetics
and titers similar to wild type (data not shown). The'mutant
virus, however, like the originally selected isolates, was
100-fold more resistant to nevirapine when assayed by syn-
cytial plaque reduction (Fig. 3), as well as by inhibition of
accumulation of' supernatant RT activity and p24 antigen
(data not shown). Although it is possible that mutations
elsewhere in the RT gene could contribute to nevirapine
resistance, these results confirm that the introduction of a
single nucleotide change into the wild-type HIV-1 genoine, of
A to G in the codon for Tyr-181 to Cys-181, respectively, is







FIG. 2. Photoaffinity probe labeling (Left) and Western blot
analysis (Right) of wild-type and mutant Cys-181 HIV-1 RTs. Ex-
perimental conditions described in Materials andMethods were used
to react BI-RJ-70 with purified recombinant enzymes. Lanes: A,
wild-type HIV-1 RT; B, mutant enzyme; lane M, prestained SDS/
PAGE molecular size standard (Bio-Rad). Positions of the het-
erodimer, p66 and pal, of HIV-1 RT are indicated.
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FIG. 3. Susceptibility to nevirapine of HIV reconstructed to
contain the Cys-181 mutation in RT. Virus was prepared by trans-
fecting Jurkat cells with mutant or wild-type proviral DNA. Nevi-
rapine susceptibility ofthe progeny virus was then assayed by plaque
reduction in CD4 HeLa (HT4-6C) cells. *, Wild type; *, Cys-181
mutant.
as that of tissue culture-selected virus grown in the presence
of the drug.
DISCUSSION
Nevirapine, a dipyridodiazepinone, is one of a class of
nonnucleoside inhibitors of HIV-1 RT that does not inhibit
HIV-2 RT or any of several other viral and mammalian DNA
polymerases (9). It inhibits p24 antigen production and syn-
cytium formation of wild-type virus in cell' culture at con-
cen'trations >8000-fold lower than the toxic dose for those
cells. Nevirapine inhibits mutant isolates of HIV resistant to
AZT and displays synergy with AZT in inhibiting AZT-
sensitive virus (12). Promising toxicologic and pharmacoki-
netic data have prompted phase I/II trials to assess the
compound as a candidate drug for HIV infection.
The unusually high rate of genetic mutation of HIV-1
portends that variants resistant to this chemotherapeutic
agent will emerge as they have to AZT. To confirm the site
at which the drug acts and to identify the mutations that are
most likely to arise in patients treated with the nonnucleoside
inhibitor nevirapine, we have selected for resistant strains in
cell culture. Resistant mutants with two strains of virus were
obtained after only a few passages of infected cells in the
presence of the drug. Selection for AZT-resistant mutants in
vitro occurs more slowly, possibly because multiple muta-
tions are necessary for a significant change in susceptibility
phenotype (7). Neither the selection of nevirapine resistance
in AZT-resistant mutants nor the selection ofresistance in the
presence of the combination of nevirapine and dideoxynu-
cleoside was examined in this study.
The cross-resistance of these nevirapine-resistant mutants
for the TIBO and 6-phenylthiouracil derivatives suggests that
these RT inhibitors bind to the same site on the enzyme. The
6-phenylthiouracil derivatives are bases that do not undergo
anabolic phosphorylation to inhibit RT and HIV-1 replication
(28), consistent with activity at a site other than the nucle-
otide-binding catalytic site. The role of'the highly conserved
amino acid sequences flanked by Tyr-181 and -188, the
nevirapine binding sites in HIV-1 RT, in the function of the
RT enzyme is not understood. These drugs that specifically
bind to sites in this domain and escape mutants that do not
bind the drugs will be useful reagents in understanding the
functional significance of these sequences in viral enzyme
activity. Although the full-length RT gene was not se-
quenced, the single mutation at amino acid 181 fully ac-
counted for the phenotypic change in susceptibility observed
in the mutants selected in culture. Two features of these
mutants suggest that they may be amenable to attack should
they arise in patients being treated with nevirapine. First,
both the mutant virus and the recombinant enzyme with the
A to G substitution retained full sensitivity to AZT and
foscarnet. The prospects of combination therapy are thus
encouraging because resistance to either drug confers no
cross-resistance to the other. Second, all resistant virus
isolates contained the same base change. This suggested that
mutation may be the only one that is well tolerated for
replication by the virus at that site and that a second
generation compound that inhibits such a mutant could
effectively control the virus infection.
Note Added In Proof. After submission of this manuscript Nunberg et
al. (29) published a report ofthe selection for HIV-1 mutants resistant
to pyridinone containing RT inhibitors with cross resistance to
nevirapine and a TIBO compound. These mutants showed 1000-fold
reductions in susceptibility and contained a lysine to asparagine
mutation at codon 103 in addition to the Cys-181 mutation. Sequenc-
ing of the nevirapine mutants has demonstrated the codon 103
mutation not to be present. It is unclear whether the lack of a codon
103 mutation and the 10-fold lower change in susceptibility with
nevirapine selection is attributable to a difference in the drugs or to
a difference in selection conditions.
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